Literature DB >> 8105383

Brief report: tumor lysis syndrome following treatment with 2-chlorodeoxyadenosine for refractory chronic lymphocytic leukemia.

E J Dann1, S Gillis, A Polliack, E Okon, D Rund, E A Rachmilewitz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8105383     DOI： 10.1056/NEJM199311183292106

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

1.  Lysis pneumonopathy associated with the use of fludarabine phosphate.

Authors:  J J Crowley; L Knight; N Charan
Journal:  West J Med       Date:  1994-12

2.  Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol.

Authors:  K A Blum; A S Ruppert; J A Woyach; J A Jones; L Andritsos; J M Flynn; B Rovin; M Villalona-Calero; J Ji; M Phelps; A J Johnson; M R Grever; J C Byrd
Journal:  Leukemia       Date:  2011-05-24       Impact factor: 11.528

3.  2-Chlorodeoxyadenosine treatment for cutaneous T-cell lymphoma.

Authors:  Małgorzata Sokołowska-Wojdyło; Magdalena Trzeciak; Jadwiga Roszkiewicz
Journal:  Dermatol Reports       Date:  2010-09-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.